Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials
2018 Gastrointestinal Cancers SymposiumThierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer (Abstracts 553, 554).
Related Videos
Mark Saunders, MD, PhD, on Colorectal Cancer: Results From the SCOT Trial
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).<...
Kyaw L. Aung, MBBS, PhD, on Pancreatic Cancer: Results From the COMPASS Trial
Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract...
Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial
Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...
David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent resu...
Manish A. Shah, MD, on Gastric Cancer: Results From the RAINFALL Trial
Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy i...
